US 11,746,379 B2
Gene fusions and gene variants associated with cancer
Daniel Rhodes, Ann Arbor, MI (US); Seth Sadis, Ann Arbor, MI (US); Peter Wyngaard, Ann Arbor, MI (US); Nikolay Khazanov, Ann Arbor, MI (US); Santhoshi Bandla, Northville, MI (US); Mark Tomilo, Ann Arbor, MI (US); Sean Eddy, Ann Arbor, MI (US); Emma Bowden, Ann Arbor, MI (US); and Jia Li, Northville, MI (US)
Assigned to Life Technologies Corporation, Carlsbad, CA (US)
Filed by Life Technologies Corporation, Carlsbad, CA (US)
Filed on Aug. 14, 2018, as Appl. No. 16/103,516.
Application 16/103,516 is a division of application No. 14/672,066, filed on Mar. 27, 2015, granted, now 10,072,298.
Application 14/672,066 is a continuation in part of application No. 14/214,300, filed on Mar. 14, 2014, abandoned.
Claims priority of provisional application 62/092,898, filed on Dec. 17, 2014.
Claims priority of provisional application 62/004,727, filed on May 29, 2014.
Claims priority of provisional application 61/993,732, filed on May 15, 2014.
Claims priority of provisional application 61/971,455, filed on Mar. 27, 2014.
Claims priority of provisional application 61/940,226, filed on Feb. 14, 2014.
Claims priority of provisional application 61/935,650, filed on Feb. 4, 2014.
Claims priority of provisional application 61/915,392, filed on Dec. 12, 2013.
Claims priority of provisional application 61/907,939, filed on Nov. 22, 2013.
Claims priority of provisional application 61/860,115, filed on Jul. 30, 2013.
Claims priority of provisional application 61/824,253, filed on May 16, 2013.
Claims priority of provisional application 61/813,465, filed on Apr. 18, 2013.
Claims priority of provisional application 61/813,182, filed on Apr. 17, 2013.
Prior Publication US 2019/0040472 A1, Feb. 7, 2019
Int. Cl. C12Q 1/6886 (2018.01); G16B 20/20 (2019.01); G16B 20/00 (2019.01); G16B 30/00 (2019.01); G16B 40/00 (2019.01)
CPC C12Q 1/6886 (2013.01) [G16B 20/20 (2019.02); C12Q 2600/156 (2013.01); C12Q 2600/158 (2013.01); C12Q 2600/16 (2013.01); G16B 20/00 (2019.02); G16B 30/00 (2019.02); G16B 40/00 (2019.02)] 5 Claims
OG exemplary drawing
 
1. A composition reaction mixture comprising a target nucleic acid and a set of primers that specifically hybridize to the target nucleic acid to flank a gene fusion, a recombinant thermostable polymerase, and dNTPs, wherein the set of primers specifically amplify a fusion between the KANK2 gene and the ALK gene comprising SEQ ID NO: 272, and wherein each primer is 15 to 40 nucleotides long and a deoxyribonucleic acid sequence comprising at least one deoxyuridine (dU) residue in place of a deoxythymidine residue.